LGALS3 and cancer: More evidence illustrates that cancer cells have unique targeting delivery and immune escape ability due to homologous cancer cells easy aggregation and interaction with the receptor and molecular (galectin-3, the endothelium-expressed β-galactoside-binding protein, tumor-associated Thomsen-Frieden Reich glycoantigen) on the surface of cancer cells [33, 34].